{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:48:42Z","timestamp":1792604922507,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12282-023-01535-5","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T06:01:49Z","timestamp":1703570509000},"page":"272-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-8823","authenticated-orcid":false,"given":"Han Hsi","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cojocaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujil","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Aloysius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"1535_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/1097-0142(1971)28:5<1087::AID-CNCR2820280502>3.0.CO;2-F","volume":"28","author":"M Arlen","year":"1971","unstructured":"Arlen M, Higinbotham N, Huvos A, Marcove R, Miller T, Shah I. Radiation-induced sarcoma of bone. Cancer. 1971;28:1087\u201399.","journal-title":"Cancer"},{"key":"1535_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.5858\/arpa.2014-0581-RS","volume":"140","author":"S Shah","year":"2016","unstructured":"Shah S, Rosa M. Radiation-associated angiosarcoma of the breast: clinical and pathologic features. Arch Pathol Lab Med. 2016;140:477\u201381.","journal-title":"Arch Pathol Lab Med"},{"key":"1535_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1005997017102","volume":"47","author":"LJA Strobbe","year":"1998","unstructured":"Strobbe LJA, Peterse HL, Van Tinteren H, Wijnmaalen A, Rutgers EJT. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat. 1998;47:101\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"1535_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/01.pas.0000126055.33916.0b","volume":"28","author":"SD Billings","year":"2004","unstructured":"Billings SD, McKenney JK, Folpe AL, Hardacre MC, Weiss SW. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol. 2004;28:781\u20138.","journal-title":"Am J Surg Pathol"},{"key":"1535_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1245\/s10434-012-2755-y","volume":"20","author":"KE Torres","year":"2013","unstructured":"Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013;20:1267\u201374.","journal-title":"Ann Surg Oncol"},{"key":"1535_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13569-017-0081-7","volume":"7","author":"RB Cohen-Hallaleh","year":"2017","unstructured":"Cohen-Hallaleh RB, Smith HG, Smith RC, Stamp GF, Al-Muderis O, Thway K, et al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin Sarcoma Res. 2017;7:15.","journal-title":"Clin Sarcoma Res"},{"key":"1535_CR7","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1245\/s10434-012-2310-x","volume":"19","author":"JM Seinen","year":"2012","unstructured":"Seinen JM, Styring E, Verstappen V, Vult Von Steyern F, Rydholm A, Suurmeijer AJH, et al. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol. 2012;19:2700\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1535_CR8","doi-asserted-by":"publisher","first-page":"798403","DOI":"10.1155\/2013\/798403","volume":"2013","author":"J Hung","year":"2013","unstructured":"Hung J, Hiniker SM, Lucas DR, Griffith KA, McHugh JB, Meirovitz A, et al. Sporadic versus radiation-associated angiosarcoma: a comparative clinicopathologic and molecular analysis of 48 cases. Sarcoma. 2013;2013:798403.","journal-title":"Sarcoma"},{"key":"1535_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0360-3016(01)02799-7","volume":"52","author":"J Yap","year":"2002","unstructured":"Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1535_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0360-3016(98)00537-9","volume":"44","author":"C Marchal","year":"1999","unstructured":"Marchal C, Weber B, De Lafontan B, Resbeut M, Mignotte H, Pabot Du Chatelard P, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys. 1999;44:113\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1535_CR11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1038\/bjc.2013.590","volume":"109","author":"SP D\u2019angelo","year":"2013","unstructured":"D\u2019angelo SP, Antonescu CR, Kuk D, Qin L, Moraco N, Carvajal RC, et al. High-risk features in radiation-associated breast angiosarcomas. Br J Cancer. 2013;109:2340\u20136.","journal-title":"Br J Cancer"},{"key":"1535_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-019-05432-4","volume":"178","author":"Y Abdou","year":"2019","unstructured":"Abdou Y, Elkhanany A, Attwood K, Ji W, Takabe K, Opyrchal M. Primary and secondary breast angiosarcoma: single center report and a meta-analysis. Breast Cancer Res Treat. 2019;178:523\u201333.","journal-title":"Breast Cancer Res Treat"},{"key":"1535_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/COC.0000000000000753","volume":"43","author":"PM Gutkin","year":"2020","unstructured":"Gutkin PM, Ganjoo KN, Lohman M, Von Eyben R, Charville GW, Nazerali RS, et al. Angiosarcoma of the breast: management and outcomes. Am J Clin Oncol. 2020;43:820\u20135.","journal-title":"Am J Clin Oncol"},{"key":"1535_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-019-05172-5","volume":"175","author":"S McClelland","year":"2019","unstructured":"McClelland S, Hatfield J, Degnin C, Chen Y, Mitin T. Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma. Breast Cancer Res Treat. 2019;175:409\u201318.","journal-title":"Breast Cancer Res Treat"},{"key":"1535_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ejca.2012.08.016","volume":"49","author":"C Lindet","year":"2013","unstructured":"Lindet C, Neuville A, Penel N, Lae M, Michels JJ, Trassard M, et al. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF\/GETO). Eur J Cancer. 2013;49:369\u201376.","journal-title":"Eur J Cancer"},{"key":"1535_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1477-7800-3-26","volume":"3","author":"M Tahir","year":"2006","unstructured":"Tahir M, Hendry P, Baird L, Qureshi NA, Ritchie D, Whitford P. Radiation induced angiosarcoma a sequela of radiotherapy for breast cancer following conservative surgery. Int Semin Surg Oncol. 2006;3:26.","journal-title":"Int Semin Surg Oncol"},{"key":"1535_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-004-2472-8","volume":"89","author":"C Rubino","year":"2005","unstructured":"Rubino C, Shamsaldin A, L\u00ea MG, Labb\u00e9 M, Guinebreti\u00e8re JM, Chavaudra J, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat. 2005;89:277\u201388.","journal-title":"Breast Cancer Res Treat"},{"key":"1535_CR18","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/S0959-8049(98)00319-0","volume":"34","author":"P Karlsson","year":"1998","unstructured":"Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer\u2014a Swedish population-based study. Eur J Cancer. 1998;34:2068\u201375.","journal-title":"Eur J Cancer"},{"key":"1535_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/153303460500400209","volume":"4","author":"JS Welsh","year":"2005","unstructured":"Welsh JS, Limmer JP, Howard SP, Diamond D, Harari PM, Tom\u00e9 W. Precautions in the use of intensity-modulated radiation therapy. Technol Cancer Res Treat. 2005;4:203\u201310.","journal-title":"Technol Cancer Res Treat"},{"key":"1535_CR20","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1002\/cncr.34377","volume":"128","author":"LA Koelmeyer","year":"2022","unstructured":"Koelmeyer LA, Gaitatzis K, Dietrich MS, Shah CS, Boyages J, McLaughlin SA, et al. Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. Cancer. 2022;128:3408\u201315.","journal-title":"Cancer"},{"key":"1535_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1089\/lrb.2014.0030","volume":"12","author":"MJ Lee","year":"2014","unstructured":"Lee MJ, Beith J, Ward L, Kilbreath S. Lymphedema following taxane-based chemotherapy in women with early breast cancer. Lymphat Res Biol. 2014;12:282\u20138.","journal-title":"Lymphat Res Biol"},{"key":"1535_CR22","first-page":"284","volume":"31","author":"FW Stewart","year":"1981","unstructured":"Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. Cancer. 1981;31:284\u201399.","journal-title":"Cancer"},{"key":"1535_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3892\/mco.2014.250","volume":"2","author":"C Dong","year":"2014","unstructured":"Dong C, Chen L. Second malignancies after breast cancer: the impact of adjuvant therapy. Mol Clin Oncol. 2014;2:331.","journal-title":"Mol Clin Oncol"},{"key":"1535_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/bjc.2017.198","volume":"117","author":"AY Zhang","year":"2017","unstructured":"Zhang AY, Judson I, Benson C, Wunder JS, Ray-Coquard I, Grimer RJ, et al. Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. Br J Cancer. 2017;117:326\u201331.","journal-title":"Br J Cancer"},{"key":"1535_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.amjsurg.2010.12.011","volume":"203","author":"N Jallali","year":"2012","unstructured":"Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012;203:156\u201361.","journal-title":"Am J Surg"},{"key":"1535_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ejso.2011.04.006","volume":"37","author":"T Pencavel","year":"2011","unstructured":"Pencavel T, Allan CP, Thomas JM, Hayes AJ. Treatment for breast sarcoma: a large, single-centre series. Eur J Surg Oncol. 2011;37:703\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"1535_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdr138","volume":"23","author":"N Penel","year":"2012","unstructured":"Penel N, Italiano A, Ray-coquard I, Chaigneau L, Delcambre C, Robin YM, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23:517\u201323.","journal-title":"Ann Oncol"},{"key":"1535_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.21140","volume":"104","author":"KM Skubitz","year":"2005","unstructured":"Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361\u20136.","journal-title":"Cancer"},{"key":"1535_CR29","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","volume":"44","author":"M Schlemmer","year":"2008","unstructured":"Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44:2433\u20136.","journal-title":"Eur J Cancer"},{"key":"1535_CR30","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269\u201374.","journal-title":"J Clin Oncol"},{"key":"1535_CR31","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/cncr.26599","volume":"118","author":"A Italiano","year":"2012","unstructured":"Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330\u20136.","journal-title":"Cancer"},{"key":"1535_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1159\/000343614","volume":"7","author":"ZG Luo","year":"2012","unstructured":"Luo ZG, Wang Q, Peng W, Hu XC, Hong XN. Advanced breast angiosarcoma completely responding to gemcitabine-containing chemotherapy. Breast Care. 2012;7:414\u20136.","journal-title":"Breast Care"},{"key":"1535_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mdr066","volume":"23","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23:501\u20138.","journal-title":"Ann Oncol"},{"key":"1535_CR34","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/cam4.5147","volume":"12","author":"S Watson","year":"2023","unstructured":"Watson S, Verret B, Ropert S, Adam J, Bahleda R, Briand S, et al. Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: a multicenter, retrospective study. Cancer Med. 2023;12:3160\u20136.","journal-title":"Cancer Med"},{"key":"1535_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/JEP.S146211","volume":"10","author":"MJ Wagner","year":"2018","unstructured":"Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Propranolol for the treatment of vascular sarcomas. J Exp Pharmacol. 2018;10:51\u20138.","journal-title":"J Exp Pharmacol"},{"key":"1535_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/PAS.0000000000000582","volume":"40","author":"SC Huang","year":"2016","unstructured":"Huang SC, Zhang L, Sung YS, Chen CL, Kao YC, Agaram NP, et al. Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations. Am J Surg Pathol. 2016;40:645\u201355.","journal-title":"Am J Surg Pathol"},{"key":"1535_CR37","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/ng.2921","volume":"46","author":"S Behjati","year":"2014","unstructured":"Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46:376\u20139.","journal-title":"Nat Genet"},{"key":"1535_CR38","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1158\/0008-5472.CAN-09-2068","volume":"69","author":"CR Antonescu","year":"2009","unstructured":"Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175\u20139.","journal-title":"Cancer Res"},{"key":"1535_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/gcc.20827","volume":"50","author":"T Guo","year":"2011","unstructured":"Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom Cancer. 2011;50:25\u201333.","journal-title":"Genes Chromosom Cancer"},{"key":"1535_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mds237","volume":"24","author":"M Agulnik","year":"2013","unstructured":"Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257\u201363.","journal-title":"Ann Oncol"},{"key":"1535_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2021.06.027","volume":"154","author":"M Agulnik","year":"2021","unstructured":"Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021;154:201\u20138.","journal-title":"Eur J Cancer"},{"key":"1535_CR42","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","volume":"27","author":"RG Maki","year":"2009","unstructured":"Maki RG, D\u2019Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133\u201340.","journal-title":"J Clin Oncol"},{"key":"1535_CR43","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/cncr.34403","volume":"128","author":"JA Thiebaud","year":"2022","unstructured":"Thiebaud JA, Ravi V, Litwin S, Schuetze SM, Movva S, Agulnik M, et al. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022;128:3516\u201322.","journal-title":"Cancer"},{"key":"1535_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","volume":"56","author":"A Koll\u00e1r","year":"2017","unstructured":"Koll\u00e1r A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56:88\u201392.","journal-title":"Acta Oncol"},{"key":"1535_CR45","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1200\/jco.2012.30.15_suppl.10019","volume":"30","author":"SP D\u2019Angelo","year":"2012","unstructured":"D\u2019Angelo SP, Antonescu CR, Keohan ML, Carvajal RD, Dickson MA, Gounder MM, et al. Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications. J Clin Oncol. 2012;30:10019. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.10019.","journal-title":"J Clin Oncol"},{"key":"1535_CR46","doi-asserted-by":"publisher","first-page":"1027696","DOI":"10.3389\/fonc.2022.1027696","volume":"12","author":"Y Gu","year":"2022","unstructured":"Gu Y, Meng J, Ju Y, You X, Sun T, Lu J, et al. Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma. Front Oncol. 2022;12:1027696.","journal-title":"Front Oncol"},{"key":"1535_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","volume":"7","author":"V Florou","year":"2019","unstructured":"Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7:213.","journal-title":"J Immunother Cancer"},{"key":"1535_CR48","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/cncr.34370","volume":"128","author":"V Ravi","year":"2022","unstructured":"Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, et al. Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study. Cancer. 2022;128:3383\u201391.","journal-title":"Cancer"},{"key":"1535_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","volume":"26","author":"CA Painter","year":"2020","unstructured":"Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26:181\u20137.","journal-title":"Nat Med"},{"key":"1535_CR50","doi-asserted-by":"publisher","first-page":"e002990","DOI":"10.1136\/jitc-2021-002990","volume":"9","author":"MJ Wagner","year":"2021","unstructured":"Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021;9:e002990.","journal-title":"J Immunother Cancer"},{"key":"1535_CR51","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1172\/JCI139080","volume":"130","author":"JY Chan","year":"2020","unstructured":"Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, et al. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Invest. 2020;130:5833.","journal-title":"J Clin Invest"},{"key":"1535_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4161\/cbt.8.4.7547","volume":"8","author":"H Kiesel","year":"2009","unstructured":"Kiesel H, M\u00fcller AMS, Schmitt-Graeff A, Veelken H. Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations. Cancer Biol Ther. 2009;8:319\u201321.","journal-title":"Cancer Biol Ther"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-023-01535-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-023-01535-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-023-01535-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:46:45Z","timestamp":1709182005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-023-01535-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1007\/s12282-023-01535-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"2 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}}]}}